An Asia-Pacific, Double Blind, Placebo Controlled, Randomised Study to Evaluate the Efficacy, Safety, and Tolerability of Tegaserod in Patients with Irritable Bowel Syndrome

Overview

Journal Gut

Specialty Gastroenterology

Date 2003 Apr 15

PMID 12692051

Citations 55

Authors

J Kellow

O Y Lee

F Y Chang

S Thongsawat

M Z Mazlam

H Yuen

K A Gwee

Y T Bak

J Jones

A Wagner

Affiliations

Soon will be listed here.

Abstract

Background: Tegaserod has been shown to be an effective therapy for the multiple symptoms of irritable bowel syndrome (IBS) in Western populations. However, little information is available regarding the use of tegaserod in the Asia-Pacific population.

Aims: To evaluate the efficacy, safety, and tolerability of tegaserod versus placebo in patients with IBS from the Asia-Pacific region.

Patients: A total of 520 patients from the Asia-Pacific region with IBS, excluding those with diarrhoea predominant IBS.

Methods: Patients were randomised to receive either tegaserod 6 mg twice daily (n=259) or placebo (n=261) for a 12 week treatment period. The primary efficacy variable (over weeks 1-4) was the response to the question: "Over the past week do you consider that you have had satisfactory relief from your IBS symptoms?" Secondary efficacy variables assessed overall satisfactory relief over 12 weeks and individual symptoms of IBS.

Results: The mean proportion of patients with overall satisfactory relief was greater in the tegaserod group than in the placebo group over weeks 1-4 (56% v 35%, respectively; p<0.0001) and weeks 1-12 (62% v 44%, respectively; p<0.0001). A clinically relevant effect was observed as early as week 1 and was maintained throughout the treatment period. Reductions in the number of days with at least moderate abdominal pain/discomfort, bloating, no bowel movements, and hard/lumpy stools were greater in the tegaserod group compared with the placebo group. Headache was the most commonly reported adverse event (12.0% tegaserod v 11.1% placebo). Diarrhoea led to discontinuation in 2.3% of tegaserod patients. Serious adverse events were infrequent (1.5% tegaserod v 3.4% placebo).

Conclusions: Tegaserod 6 mg twice daily is an effective, safe, and well tolerated treatment for patients in the Asia-Pacific region suffering from IBS and whose main bowel symptom is not diarrhoea.

Citing Articles

A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of DA-9701 (Motilitone) in Patients With Constipation-type Irritable Bowel Syndrome and Functional Dyspepsia Overlap: A Pilot Study.

Lee J, Kim N, Yoon H, Shin C, Park Y, Lee D J Neurogastroenterol Motil. 2022; 28(2):265-275.

PMID: 35232894 PMC: 8978125. DOI: 10.5056/jnm20236.

Low FODMAP Diet for Functional Gastrointestinal Symptoms in Quiescent Inflammatory Bowel Disease: A Systematic Review of Randomized Controlled Trials.

Grammatikopoulou M, Goulis D, Gkiouras K, Nigdelis M, Papageorgiou S, Papamitsou T Nutrients. 2020; 12(12).

PMID: 33260902 PMC: 7760970. DOI: 10.3390/nu12123648.

Tegaserod for the Treatment of Irritable Bowel Syndrome.

Madia V, Messore A, Saccoliti F, Tudino V, De Leo A, De Vita D Antiinflamm Antiallergy Agents Med Chem. 2019; 19(4):342-369.

PMID: 31518227 PMC: 7579269. DOI: 10.2174/1871523018666190911121306.

Second Asian Consensus on Irritable Bowel Syndrome.

Gwee K, Gonlachanvit S, Ghoshal U, Chua A, Miwa H, Wu J J Neurogastroenterol Motil. 2019; 25(3):343-362.

PMID: 31327218 PMC: 6657923. DOI: 10.5056/jnm19041.

What Is New in Rome IV.

Schmulson M, Drossman D J Neurogastroenterol Motil. 2017; 23(2):151-163.

PMID: 28274109 PMC: 5383110. DOI: 10.5056/jnm16214.

References

Naliboff B, Fullerton S, Mayer E . Measurement of symptoms in irritable bowel syndrome clinical trials. Am J Med. 1999; 107(5A):81S-84S. DOI: 10.1016/s0002-9343(99)00084-4. View

Chatellier G, Zapletal E, Lemaitre D, Menard J, Degoulet P . The number needed to treat: a clinically useful nomogram in its proper context. BMJ. 1996; 312(7028):426-9. PMC: 2350093. DOI: 10.1136/bmj.312.7028.426. View

Hawkey C . Irritable bowel syndrome clinical trial design: future needs. Am J Med. 1999; 107(5A):98S-102S. DOI: 10.1016/s0002-9343(99)00087-x. View

Prather C, Camilleri M, Zinsmeister A, McKinzie S, Thomforde G . Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology. 2000; 118(3):463-8. DOI: 10.1016/s0016-5085(00)70251-4. View

Whitehead W . Patient subgroups in irritable bowel syndrome that can be defined by symptom evaluation and physical examination. Am J Med. 1999; 107(5A):33S-40S. DOI: 10.1016/s0002-9343(99)00078-9. View

Drossman D . Do psychosocial factors define symptom severity and patient status in irritable bowel syndrome?. Am J Med. 1999; 107(5A):41S-50S. DOI: 10.1016/s0002-9343(99)00081-9. View

Muller-Lissner S, Fumagalli I, Bardhan K, Pace F, Pecher E, Nault B . Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther. 2001; 15(10):1655-66. DOI: 10.1046/j.1365-2036.2001.01094.x. View

Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S . Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther. 2001; 15(11):1745-51. DOI: 10.1046/j.1365-2036.2001.01103.x. View

Talley N . Serotoninergic neuroenteric modulators. Lancet. 2002; 358(9298):2061-8. DOI: 10.1016/S0140-6736(01)07103-3. View

10.

Pan G, Lu S, Ke M, Han S, Guo H, Fang X . Epidemiologic study of the irritable bowel syndrome in Beijing: stratified randomized study by cluster sampling. Chin Med J (Engl). 2002; 113(1):35-9. View

11.

Fidelholtz J, Smith W, Rawls J, Shi Y, Zack A, Ruegg P . Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. Am J Gastroenterol. 2002; 97(5):1176-81. DOI: 10.1111/j.1572-0241.2002.05692.x. View

12.

Schikowski A, Thewissen M, Mathis C, Enck P . Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil. 2002; 14(3):221-7. DOI: 10.1046/j.1365-2982.2002.00328.x. View

13.

Morganroth J, Ruegg P, Dunger-Baldauf C, Appel-Dingemanse S, Bliesath H, Lefkowitz M . Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects. Am J Gastroenterol. 2002; 97(9):2321-7. DOI: 10.1111/j.1572-0241.2002.05986.x. View

14.

Novick J, Miner P, Krause R, Glebas K, Bliesath H, Ligozio G . A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2002; 16(11):1877-88. DOI: 10.1046/j.1365-2036.2002.01372.x. View

15.

Coffin B, Farmachidi J, Rueegg P, Bastie A, Bouhassira D . Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther. 2003; 17(4):577-85. DOI: 10.1046/j.1365-2036.2003.01449.x. View

16.

Nguyen A, Camilleri M, Kost L, Metzger A, Sarr M, Hanson R . SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther. 1997; 280(3):1270-6. View

17.

Drossman D, Whitehead W, Camilleri M . Irritable bowel syndrome: a technical review for practice guideline development. Gastroenterology. 1997; 112(6):2120-37. DOI: 10.1053/gast.1997.v112.agast972120. View

18.

Grider J, Foxx-Orenstein A, Jin J . 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology. 1998; 115(2):370-80. DOI: 10.1016/s0016-5085(98)70203-3. View

19.

Gershon M . Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther. 1999; 13 Suppl 2:15-30. View

20.

Thompson W, Longstreth G, Drossman D, Heaton K, Irvine E, Muller-Lissner S . Functional bowel disorders and functional abdominal pain. Gut. 1999; 45 Suppl 2:II43-7. PMC: 1766683. DOI: 10.1136/gut.45.2008.ii43. View